Pharma BD Deal Intelligence
JW Therapeutics agreed to transfer regional (China) rights to ARTEMIS-based AFP- and GPC3-targeted cell therapies back to Eureka Therapeutics' Hong Kong subsidiary, exiting the two solid tumor programs. Eureka pays USD 10 million upfront, with JW eligible for up to USD 100 million in additional commercial milestones contingent on a qualifying third-party transaction and subsequent sales targets. JW also receives 10% of proceeds attributable to the transferred products and territory from qualifying third-party agreements entered by Eureka within 24 months of closing, with revenue sharing continuing six years after each qualifying transaction.
← Browse all deals · How we score deals
More: 2026 deals